ACT‐1004‐1239, a first‐in‐class CXCR7 antagonist with both immunomodulatory and promyelinating effects for the treatment of inflammatory demyelinating diseases
Author:
Affiliation:
1. Idorsia Pharmaceuticals Ltd. Allschwil Switzerland
Publisher
Wiley
Subject
Genetics,Molecular Biology,Biochemistry,Biotechnology
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1096/fj.202002465R
Reference66 articles.
1. Current multiple sclerosis treatments have improved our understanding of MS autoimmune pathogenesis
2. Attempts to Overcome Remyelination Failure: Toward Opening New Therapeutic Avenues for Multiple Sclerosis
3. A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
4. Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
5. Teriflunomide in the treatment of multiple sclerosis: current evidence and future prospects
Cited by 17 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Quantification of increased biologically active CXCL12α plasma concentrations after ACKR3 antagonist treatment in humans;Clinical and Translational Science;2024-01-27
2. The Role of Atypical Chemokine Receptors in Neuroinflammation and Neurodegenerative Disorders;International Journal of Molecular Sciences;2023-11-18
3. Regulation of the Hippo/YAP axis by CXCR7 in the tumorigenesis of gastric cancer;Journal of Experimental & Clinical Cancer Research;2023-11-10
4. Conformational dynamics underlying Atypical Chemokine Receptor 3 activation;2023-07-17
5. New pairings and deorphanization among the atypical chemokine receptor family — physiological and clinical relevance;Frontiers in Immunology;2023-04-20
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3